Orchid Pharma Q2 FY27 Monitoring Agency Report Details Full QIP Utilization
Orchid Pharma Ltd · Others (Uncategorized) · 14 Nov 2026, 12:34 am
Orchid Pharma Q2 FY27 Monitoring Agency Report Details Full QIP Utilization CARE Ratings reported that Orchid Pharma Limited has fully utilized its revised net QIP proceeds of ₹394.54 crore as of 30th Sep'26, with zero unutilized funds remaining. Deployments include ₹195.46 crore for debt repayment, ₹135.00 crore for investment in subsidiary Orchid Bio Pharma's Jammu plant, ₹63.72 crore for general corporate purposes, and ₹0.36 crore for the Alathur API unit. Commercial operations at the Jammu manufacturing facility face project implementation delays and are now expected to commence by Feb'27 due to prolonged land acquisition agreements.
Original exchange filing (PDF)
More announcements from Orchid Pharma Ltd
- Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company') · 18 Nov 2026
- Board Comments on fine levied by Stock Exchanges · 17 Nov 2026
- Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026 · 17 Nov 2026
- Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP) · 14 Nov 2026
- Declaration of Financial results for quarter and half year ended on September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026 · 17 Nov 2026
